vs
Datadog（DDOG）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
Datadog的季度营收约是EXACT SCIENCES CORP的1.1倍（$953.2M vs $878.4M），Datadog净利率更高（4.9% vs -9.8%，领先14.7%），Datadog同比增速更快（29.2% vs 23.1%），Datadog自由现金流更多（$318.2M vs $120.4M），过去两年Datadog的营收复合增速更高（24.9% vs 17.4%）
Datadog是一家美国企业，为云级应用提供可观测性服务，旗下SaaS数据分析平台可实现对服务器、数据库、各类工具及服务的统一监控。公司成立并总部位于纽约，目前在纳斯达克证券交易所公开上市。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
DDOG vs EXAS — 直观对比
营收规模更大
DDOG
是对方的1.1倍
$878.4M
营收增速更快
DDOG
高出6.1%
23.1%
净利率更高
DDOG
高出14.7%
-9.8%
自由现金流更多
DDOG
多$197.7M
$120.4M
两年增速更快
DDOG
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $953.2M | $878.4M |
| 净利润 | $46.6M | $-86.0M |
| 毛利率 | 80.4% | 70.1% |
| 营业利润率 | 1.0% | -9.4% |
| 净利率 | 4.9% | -9.8% |
| 营收同比 | 29.2% | 23.1% |
| 净利润同比 | 2.1% | 90.1% |
| 每股收益（稀释后） | $0.13 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DDOGEXAS
| Q4 25 | $953.2M | $878.4M | ||
| Q3 25 | $885.7M | $850.7M | ||
| Q2 25 | $826.8M | $811.1M | ||
| Q1 25 | $761.6M | $706.8M | ||
| Q4 24 | $737.7M | $713.4M | ||
| Q3 24 | $690.0M | $708.7M | ||
| Q2 24 | $645.3M | $699.3M | ||
| Q1 24 | $611.3M | $637.5M |
净利润DDOGEXAS
| Q4 25 | $46.6M | $-86.0M | ||
| Q3 25 | $33.9M | $-19.6M | ||
| Q2 25 | $2.6M | $-1.2M | ||
| Q1 25 | $24.6M | $-101.2M | ||
| Q4 24 | $45.6M | $-864.6M | ||
| Q3 24 | $51.7M | $-38.2M | ||
| Q2 24 | $43.8M | $-15.8M | ||
| Q1 24 | $42.6M | $-110.2M |
毛利率DDOGEXAS
| Q4 25 | 80.4% | 70.1% | ||
| Q3 25 | 80.1% | 68.6% | ||
| Q2 25 | 79.9% | 69.3% | ||
| Q1 25 | 79.3% | 70.8% | ||
| Q4 24 | 80.5% | 69.0% | ||
| Q3 24 | 80.0% | 69.4% | ||
| Q2 24 | 80.9% | 69.8% | ||
| Q1 24 | 82.0% | 70.0% |
营业利润率DDOGEXAS
| Q4 25 | 1.0% | -9.4% | ||
| Q3 25 | -0.7% | -3.0% | ||
| Q2 25 | -4.3% | -0.3% | ||
| Q1 25 | -1.6% | -13.6% | ||
| Q4 24 | 1.3% | -122.8% | ||
| Q3 24 | 2.9% | -5.6% | ||
| Q2 24 | 2.0% | -3.8% | ||
| Q1 24 | 2.0% | -16.7% |
净利率DDOGEXAS
| Q4 25 | 4.9% | -9.8% | ||
| Q3 25 | 3.8% | -2.3% | ||
| Q2 25 | 0.3% | -0.1% | ||
| Q1 25 | 3.2% | -14.3% | ||
| Q4 24 | 6.2% | -121.2% | ||
| Q3 24 | 7.5% | -5.4% | ||
| Q2 24 | 6.8% | -2.3% | ||
| Q1 24 | 7.0% | -17.3% |
每股收益（稀释后）DDOGEXAS
| Q4 25 | $0.13 | $-0.45 | ||
| Q3 25 | $0.10 | $-0.10 | ||
| Q2 25 | $0.01 | $-0.01 | ||
| Q1 25 | $0.07 | $-0.54 | ||
| Q4 24 | $0.14 | $-4.69 | ||
| Q3 24 | $0.14 | $-0.21 | ||
| Q2 24 | $0.12 | $-0.09 | ||
| Q1 24 | $0.12 | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $401.3M | $964.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.7B | $2.4B |
| 总资产 | $6.6B | $5.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DDOGEXAS
| Q4 25 | $401.3M | $964.7M | ||
| Q3 25 | $540.6M | $1.0B | ||
| Q2 25 | $489.0M | $858.4M | ||
| Q1 25 | $1.1B | $786.2M | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $337.4M | $1.0B | ||
| Q2 24 | $411.0M | $946.8M | ||
| Q1 24 | $282.2M | $652.1M |
股东权益DDOGEXAS
| Q4 25 | $3.7B | $2.4B | ||
| Q3 25 | $3.4B | $2.5B | ||
| Q2 25 | $3.2B | $2.5B | ||
| Q1 25 | $2.9B | $2.4B | ||
| Q4 24 | $2.7B | $2.4B | ||
| Q3 24 | $2.6B | $3.2B | ||
| Q2 24 | $2.4B | $3.2B | ||
| Q1 24 | $2.2B | $3.1B |
总资产DDOGEXAS
| Q4 25 | $6.6B | $5.9B | ||
| Q3 25 | $6.1B | $5.9B | ||
| Q2 25 | $5.8B | $5.8B | ||
| Q1 25 | $6.0B | $5.7B | ||
| Q4 24 | $5.8B | $5.9B | ||
| Q3 24 | $4.6B | $6.7B | ||
| Q2 24 | $4.4B | $6.7B | ||
| Q1 24 | $4.1B | $6.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $327.1M | $151.7M |
| 自由现金流经营现金流 - 资本支出 | $318.2M | $120.4M |
| 自由现金流率自由现金流/营收 | 33.4% | 13.7% |
| 资本支出强度资本支出/营收 | 0.9% | 3.6% |
| 现金转化率经营现金流/净利润 | 7.02× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $356.8M |
8季度趋势，按日历期对齐
经营现金流DDOGEXAS
| Q4 25 | $327.1M | $151.7M | ||
| Q3 25 | $251.5M | $219.9M | ||
| Q2 25 | $200.1M | $89.0M | ||
| Q1 25 | $271.5M | $30.8M | ||
| Q4 24 | $265.2M | $47.1M | ||
| Q3 24 | $228.7M | $138.7M | ||
| Q2 24 | $164.4M | $107.1M | ||
| Q1 24 | $212.3M | $-82.3M |
自由现金流DDOGEXAS
| Q4 25 | $318.2M | $120.4M | ||
| Q3 25 | $234.7M | $190.0M | ||
| Q2 25 | $184.9M | $46.7M | ||
| Q1 25 | $262.8M | $-365.0K | ||
| Q4 24 | $257.5M | $10.7M | ||
| Q3 24 | $220.3M | $112.6M | ||
| Q2 24 | $160.0M | $71.2M | ||
| Q1 24 | $198.1M | $-120.0M |
自由现金流率DDOGEXAS
| Q4 25 | 33.4% | 13.7% | ||
| Q3 25 | 26.5% | 22.3% | ||
| Q2 25 | 22.4% | 5.8% | ||
| Q1 25 | 34.5% | -0.1% | ||
| Q4 24 | 34.9% | 1.5% | ||
| Q3 24 | 31.9% | 15.9% | ||
| Q2 24 | 24.8% | 10.2% | ||
| Q1 24 | 32.4% | -18.8% |
资本支出强度DDOGEXAS
| Q4 25 | 0.9% | 3.6% | ||
| Q3 25 | 1.9% | 3.5% | ||
| Q2 25 | 1.8% | 5.2% | ||
| Q1 25 | 1.1% | 4.4% | ||
| Q4 24 | 1.1% | 5.1% | ||
| Q3 24 | 1.2% | 3.7% | ||
| Q2 24 | 0.7% | 5.1% | ||
| Q1 24 | 2.3% | 5.9% |
现金转化率DDOGEXAS
| Q4 25 | 7.02× | — | ||
| Q3 25 | 7.42× | — | ||
| Q2 25 | 75.58× | — | ||
| Q1 25 | 11.02× | — | ||
| Q4 24 | 5.82× | — | ||
| Q3 24 | 4.42× | — | ||
| Q2 24 | 3.75× | — | ||
| Q1 24 | 4.98× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DDOG
| North America | $678.7M | 71% |
| International | $274.5M | 29% |
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
